BBB delivery

Pericyte loss in cognitive-impairment-prone hippocampal regions precedes blood-brain barrier breakdown and is detectable before clinical Alzheimer disease symptom onset; this provides a timing-window for biomarker-driven intervention.

ATV:TREM2 agonist antibody brain shuttle construct (ATV fused to anti-TREM2 agonist) achieves 50-fold higher brain exposure than unmodified antibody and shows superior microglial activation and plaque reduction in 5xFAD mice compared with anti-TREM2 alone, providing in vivo validation of the ATV platform for TREM2...

Covers Genentech's low-affinity anti-TfR antibodies that facilitate BBB transcytosis without inhibiting transferrin or HFE binding; foundational patent on affinity-tuning TfR antibodies to escape lysosomal trapping and achieve CNS delivery.

Granted US patent on specific sequence-defined bispecific antibodies that bivalently bind Aβ plaques and monovalently bind TfR1; covers the structural format used in trontinemab for enhanced CNS delivery.

Re-engineering of the anti-transferrin receptor antibody 8D3 to monovalent binding increases BBB transcytosis efficiency 10-fold over bivalent format; monovalent TfR engagement avoids receptor downregulation and enables superior brain uptake of antibody-drug conjugates.

Core platform patent for Roche Brain Shuttle (BrainShuttle): monovalent single-chain Fab against TfR1 fused to therapeutic IgG; monovalent format prevents lysosomal sorting, enabling 55-fold increase in brain Aβ engagement versus parent antibody.

Foundational composition patent for gantenerumab, a fully human IgG1 anti-Aβ antibody generated via MorphoSys HuCAL technology; binds dual N-terminal (AEFRHDSGY) and central (VHHQKLVFFAEDVG) Aβ epitopes on aggregated fibrillar forms.

Reducing anti-TfR antibody affinity for transferrin receptor enhances receptor-mediated transcytosis and brain uptake; bispecific anti-TfR/BACE1 antibody lowers brain Aβ in mice after single systemic dose. Mechanistic foundation of the Brain Shuttle delivery class.

Anti-TfR/BACE1 bispecific antibodies cross BBB in cynomolgus monkeys; reduce CSF and brain-tissue Aβ in dose-dependent fashion correlated with brain antibody concentration. Translates Yu 2011 mouse PK/PD into NHP, supporting clinical Brain Shuttle development.

P-glycoprotein expression at the blood-brain barrier declines with age and is further reduced in Alzheimer's disease, contributing to amyloid-beta accumulation by impaired cerebral efflux; this is the same transporter that excludes most oncology drugs from glioblastoma at the infiltrative margin.

AHEAD A3 (NCT04468659) is a Phase III preclinical-AD lecanemab trial in cognitively-unimpaired adults with intermediate amyloid; eligibility uses APOE genotype stratification, with the 2022 SAP amendment refining APOE4-positive arm allocation in line with APOE4-specific BBB/pericyte evidence.

Claudin-5 and occludin expression is reduced in cerebral microvasculature of early Alzheimer's disease post-mortem brain, paralleling the tight-junction breakdown observed in glioblastoma peritumoral vessels and consistent with a shared mechanism of BBB compromise across these otherwise unrelated diseases.

Roche-Denali Brain Shuttle gantenerumab (Trontinemab / RG6102, NCT04374253) program scope reflects BBB-transcytosis-as-delivery-target architecture; following Montagne 2020 APOE4-stratified BBB evidence, program decision-making prioritizes APOE4-stratified PK/PD readouts and BBB-permeability biomarker integration.

Roche Trontinemab (RG6102) program pivoted post-CLARITY-AD to position Brain Shuttle gantenerumab-derivative as next-generation early-stage AD MAb with reduced ARIA risk profile; explicit positioning vs. lecanemab benchmark.

Recent Advances in Antibody Therapy for Alzheimer's Disease: Focus on Bispecific Antibodies. — Alzheimer's disease (AD) impacts more than half a million people worldwide, with no cure available. The regulatory approval of three anti-amyloid monoclonal antibodies (mAbs), including aducanumab, lecanemab, and...

Radionuclide Selection Influences Imaging Outcomes in Immuno-PET with a Brain-Penetrating Anti-Amyloid-β Antibody. — Bispecific antibodies exploiting receptor-mediated transcytosis offer a promising strategy to overcome limited blood-brain barrier permeability in Alzheimer disease immunotherapy and imaging....

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer's Disease: Where Are We Now? — Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by decreased amyloid-beta (Aβ) clearance, enhanced Aβ aggregation, an increased risk of amyloid-related imaging abnormalities (ARIA), and...

Transferrin-receptor shuttle designs can increase brain exposure of anti-BACE or anti-amyloid antibodies in preclinical systems, but clinical translation remains unresolved.

Focused ultrasound blood-brain barrier opening may increase regional amyloid removal during aducanumab treatment, but current human evidence is very small and not sufficient for clinical translation.

Anti-TfR/BACE1 bispecific antibodies cross the blood-brain barrier and reduce brain amyloid-beta levels in human TfR knock-in mice.

High-affinity anti-TfR antibodies remain associated with the blood-brain barrier vasculature, whereas lower-affinity variants are released into the brain parenchyma.

Reducing the affinity of an antibody for the transferrin receptor (TfR) enhances its receptor-mediated transcytosis across the blood-brain barrier (BBB) into the mouse brain.

Bapineuzumab (anti-Aβ monoclonal) failed primary endpoints in two Phase III trials in mild-moderate Alzheimer's. ARIA-E vasogenic edema rate was elevated in APOE4 carriers, foreshadowing the BBB-permeability / APOE4 axis later articulated by Montagne 2020.

The reduction of brain amyloid-beta by anti-TfR/BACE1 antibodies in human TfR knock-in mice is dependent on the antibody's affinity for the transferrin receptor.

The Brain Shuttle version of an anti-Aβ antibody, utilizing a monovalent binding mode to the transferrin receptor (TfR), increases β-Amyloid target engagement in an Alzheimer's disease mouse model by 55-fold compared to the parent antibody.